4WEB, Inc. v. NuVasive, Inc.

District Court, S.D. California·Decided November 8, 2024·No. 3:24-cv-01021·Unknown

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 4WEB, INC., Case No.: 24-CV-1021 JLS (MMP)

12 Plaintiff, ORDER GRANTING PLAINTIFF’S 13 v. MOTION TO SUBSTITUTE OR, IN THE ALTERNATIVE, ADD 4WEB, 14 NUVASIVE, INC., LLC AS A PLAINTIFF 15 Defendant. (ECF No. 71) 16 17 18 19 20 Presently before the Court are Plaintiff 4WEB, Inc.’s Motion to Substitute or, in the 21 Alternative, Add 4Web, LLC as a Plaintiff (“Mot.,” ECF No. 71) and Memorandum of 22 Points and Authorities in Support thereof (“Mem.,” ECF No. 71-1), to which Defendant 23 NuVasive, Inc. filed an Opposition (“Opp’n,” ECF No. 78) and Plaintiff filed a Reply 24 (“Reply,” ECF No. 80). After considering the Parties’ arguments and the law, the Court 25 GRANTS the Motion. 26 Plaintiff brought this patent infringement action in the United States District Court 27 for the Eastern District of Texas on April 25, 2023. See ECF No. 1. Initially asserted were 28 / / / 1 over 100 claims across eleven patents relating to spinal implant technology. See ECF 2 No. 21 (“FAC”). The patents at issue are U.S. Patent Nos. 8,430,930 (the “’930 patent”); 3 9,999,516 (the “’516 patent”); 9,545,317 (the “’317 patent”); 11,278,421 (the “’421 4 patent”); 9,271,845 (the “’845 patent”); 9,549,823 (the “’823 patent”); 9,572,669 (the 5 “’669 patent”); 9,757,235 (the “’235 patent”); 10,849,756 (the “’756 patent”); 9,987,137 6 (the “’137 patent”); and 9,636,226 (the “’226 patent”) (collectively, “Patents-in-Suit”). See 7 id. ¶¶ 71, 82, 92, 102, 112, 123, 134, 145, 156, 167, 178. At the time the suit was filed, 8 Plaintiff alleged that it “own[ed] by assignment all right, title and interest in” the 9 Patents-in-Suit. Id. ¶¶ 35–44. 10 Plaintiff now represents that it no longer possesses any ownership interest in the 11 Patents-in-Suit as it assigned all rights in the patents to 4Web, LLC (“Assignee”)—a 12 business entity whose parent companies are Plaintiff and CF 4WB Holdings LLC—under 13 a patent assignment dated March 18, 2024 (“Patent Assignment”). See Mem. at 2 (citing 14 Ex. 1 (“Assignment”), ECF No. 71-3). In the Patent Assignment, Plaintiff acknowledged 15 that it “does hereby contribute, assign, transfer, and convey unto 4Web, LLC . . . all right, 16 title, and interest that exist today and may exist in the future in and to” a set of several 17 dozen provisional patent applications, patent applications, and patents, including all of the 18 Patents-in-Suit. See Assignment at 4–8. Plaintiff further agreed to assign “all causes of 19 action and other enforcement rights for (1) damages, (2) injunctive relief, and (3) any other 20 remedies of any kind for past, current, and future infringement . . . .” Id. at 9. Plaintiff 21 recorded these assignments with the United States Patent and Trademark Office on April 5, 22 2024. See Ex. 2 (“USPTO Recordation”), ECF No. 71-3. 23 24 25 1 On September 24, 2024, the Court granted in part and denied in part Defendant’s Motion for Patent Claim Reduction, requiring Plaintiff to select no more than thirty-two (32) of its presently asserted claims 26 within fourteen (14) days. See ECF No. 103 at 7–8. The Court is under the impression that Plaintiff has satisfied that requirement. See ECF No. 104 at 2 (noting a joint proposed date of October 9, 2024, for 27 Plaintiff to narrow its claims to a total of 32). 28 1 Plaintiff now wishes to substitute or, in the alternative, add Assignee as a plaintiff in 2 the instant suit. Plaintiff’s argument is simple: It contends that Assignee now “has sole 3 standing to sue,” so substitution under Federal Rule of Civil Procedure 25(c) is proper to 4 cure the jurisdictional defect created by the Patent Assignment. Mem. at 4–5. Because the 5 authenticity of the Patent Assignment is uncontested, Plaintiff argues that Defendant has 6 no legitimate basis for disputing the Motion. See Reply at 3. 7 Defendant does not necessarily contest substitution of Assignee as a conceptual 8 matter, but rather argues that the Court should postpone consideration of the Motion until 9 further discovery is conducted. Specifically, Defendant seeks discovery related to the 10 business relationships between Assignee; CF 4WB Holdings, LLC; and Fortress 11 Investment Group, a self-described “global leader in litigation finance.” Opp’n at 3–4 12 (quoting Fortress’s website). Questions related to these relationships arose after Defendant 13 conducted an independent investigation revealing a connection between three individuals 14 listed as Managers of Assignee and CF 4WB Holdings, LLC who are also believed to be 15 affiliated with Fortress. Id. at 2–3 (citing filings with the Texas Secretary of State). By 16 Defendant’s logic, these unearthed connections coupled with a gap in knowledge as to each 17 entity’s true interest in the Patents-in-Suit entitles Defendant to additional discovery prior 18 to resolution of the instant Motion. See id. at 5. 19 Federal Rule of Civil Procedure 25(c) provides that “[i]f an interest is transferred, 20 the action may be continued by or against the original party unless the court, on motion, 21 orders the transferee to be substituted in the action or joined with the original party.” 22 Rule 25(c) is permissive because it “is not designed to create new relationships among 23 parties to a suit but is designed to allow the action to continue unabated when an interest 24 in the lawsuit changes hands.” In re Bernal, 207 F.3d 595, 598 (9th Cir. 2000) (quoting In 25 re Covington Grain Co., Inc., 638 F.2d 1362, 1364 (5th Cir. 1981)). Quoting a leading 26 treatise, the Ninth Circuit has observed: 27 The most significant feature of Rule 25(c) is that it does not 28 require that anything be done after an interest has been 1 transferred. The action may be continued by or against the 2 original party, and the judgment will be binding on this successor 3 in interest even though he is not named. An order of joinder is 4 merely a discretionary determination by the trial court that the 5 transferee’s presence would facilitate the conduct of the 6 litigation. 7 Id. (quoting 7C CHARLES ALAN WRIGHT, ARTHUR R. MILLER & MARY KAY KANE, 8 FEDERAL PRACTICE AND PROCEDURE § 1958 (2d Ed. 1986)). In other words, “[t]he rule 9 ‘leaves the substitution decision to [the trial] court’s sound discretion.’” Uniloc USA Inc. 10 v. LG Elecs. U.S.A. Inc., Nos. 18-cv-06737-JST; 18-cv-06739-JST; 18-cv-06740-JST, 11 2019 WL 690290, at *1 (N.D. Cal. Feb. 19, 2019) (quoting In re Bernal, 207 F.3d at 598). 12 Invocation of Rule 25(c) is not uncommon in patent litigation; indeed, sometimes it 13 may be necessary. “The general rule in federal cases is that a plaintiff must have initial 14 standing and ‘continue to have a “personal stake in the outcome” of the lawsuit.’” 15 Schreiber Foods, Inc. v. Beatrice Cheese, Inc., 402 F.3d 1198, 1203 (Fed. Cir. 2005) 16 (quoting Spencer v. Kemna, 523 U.S. 1, 7 (1998)). Under the Patent Act, “[a] patentee 17 shall have remedy by civil action for infringement of his patent,” 35 U.S.C. § 281, but the 18 definition of a patentee “includes not only the patentee to whom the patent was issued but 19 also the successors in title to the patentee,” id. § 100(d).

Free access — add to your briefcase to read the full text and ask questions with AI

4WEB, Inc. v. NuVasive, Inc., (S.D. Cal. 2024).

4WEB, Inc. v. NuVasive, Inc. (4WEB, Inc. v. NuVasive, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related